Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 20.00K | 16.02M | 0.00 | 0.00 | 0.00 | 12.06K |
Gross Profit | -15.98M | 16.00M | -4.03M | -134.03K | -227.27K | -188.16K |
EBITDA | -9.84M | 5.75M | -12.35M | -13.55M | -13.73M | -6.65M |
Net Income | -12.05M | 3.59M | -12.51M | -13.58M | -16.39M | -8.09M |
Balance Sheet | ||||||
Total Assets | 34.02M | 36.48M | 13.71M | 18.68M | 18.06M | 15.16M |
Cash, Cash Equivalents and Short-Term Investments | 24.11M | 26.79M | 2.45M | 5.96M | 7.85M | 1.19M |
Total Debt | 159.02K | 57.17K | 106.89K | 105.78K | 209.41K | 362.12K |
Total Liabilities | 10.32M | 10.72M | 7.60M | 7.27M | 8.83M | 8.16M |
Stockholders Equity | 23.70M | 25.76M | 6.11M | 11.41M | 9.22M | 7.00M |
Cash Flow | ||||||
Free Cash Flow | -7.78M | 8.55M | -9.56M | -10.43M | -10.95M | -7.45M |
Operating Cash Flow | -7.77M | 8.56M | -9.56M | -10.43M | -10.89M | -7.32M |
Investing Cash Flow | -19.99M | -22.66M | 0.00 | 6.38K | -157.02K | -244.44K |
Financing Cash Flow | 250.52K | 15.50M | 5.97M | 8.62M | 17.80M | 5.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | ¥338.68B | 10.98 | -2.99% | 2.59% | 11.79% | -10.11% | |
56 Neutral | $8.55M | 4.67 | -41.13% | ― | ― | ― | |
54 Neutral | $14.43M | ― | -195.46% | ― | -29.46% | 2.71% | |
45 Neutral | $9.43M | ― | -45.38% | ― | -48.61% | 32.18% | |
39 Underperform | $11.07M | ― | -285.79% | ― | ― | 23.65% |
Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of KIO-301 for treating retinitis pigmentosa, aiming to restore vision in patients with severe vision loss. The ABACUS-2 trial will assess the drug’s safety and efficacy across multiple centers in Australia, utilizing a unique photoswitch mechanism that could work for various gene mutations associated with retinal diseases. This innovative approach, supported by Théa Open Innovation, offers hope for a breakthrough in treating inherited retinal conditions.